For the year ending 2025-12-31, ACXP had $3,849,387 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -7,966,538 |
| Share-based compensation | 1,247,401 |
| Share-based payments to vendors | 322,319 |
| Other receivable | -2,710 |
| Prepaid expenses | -15,105 |
| Accounts payable and accrued expenses | -408,779 |
| Net cash used in operating activities | -6,787,782 |
| Reverse stock split fractional share adjustment | 1,040 |
| Proceeds from warrant inducement, net of issuance costs | 2,480,553 |
| Proceeds from warrant exercise | 1,360,544 |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | 3,808,439 |
| Proceeds from 2025 march registered direct offering, net of issuance costs | 889,420 |
| Proceeds from 2025 january registered direct offering, net of issuance costs | 2,099,253 |
| Net cash provided by financing activities | 10,637,169 |
| Net increase/(decrease) in cash | 3,849,387 |
| Cash at beginning of year | 3,706,713 |
| Cash at end of year | 7,556,100 |
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)